Pacira Pharma (PCRX) Posts Wider than Expected Loss; Reiterates FY11 Outlook
Tweet
Share
E-mail
Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) reported Q1 loss of $0.98, $0.45 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.16 million.
Reiterates FY11 revs outlook.
Reiterates FY11 revs outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Fluence Energy cuts fiscal 2026 revenue outlook on supply chain woes
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
